Press coverage about Horizon Pharma PLC (NASDAQ:HZNP) has been trending somewhat positive this week, Alpha One reports. The research firm, a service of Accern, identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Alpha One ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Horizon Pharma PLC earned a news sentiment score of 0.15 on Alpha One’s scale. Alpha One also assigned press coverage about the biopharmaceutical company an impact score of 91 out of 100, indicating that recent press coverage is extremely likely to have an effect on the company’s share price in the immediate future.
Here are some of the news stories that may have effected AlphaOne Sentiment’s analysis:
- Horizon Pharma Ord (HZNP) A Look at Technical Overview (nyhetsbanken.info)
- Shares in Horizon Pharma PLC (HZNP) Acquired by Trexquant Investment LP (hypelee.com)
- Cantor Fitzgerald reiterated Overweight on these pharma stocks: Impax Laboratories Inc(NASDAQ:IPXL) and Horizon Pharma PLC(NASDAQ:HZNP) (fxdailyreport.com)
- Valeant: Stop Looking in the Rearview Mirror! (finance.yahoo.com)
- Horizon Pharma PLC (HZNP) Coverage Initiated by Analysts at Cantor Fitzgerald (americanbankingnews.com)
A number of equities research analysts have recently weighed in on HZNP shares. Mizuho cut their price objective on Horizon Pharma PLC from $25.00 to $22.00 and set a “buy” rating on the stock in a research report on Tuesday, February 28th. Cantor Fitzgerald assumed coverage on Horizon Pharma PLC in a research note on Friday. They issued an “overweight” rating and a $13.00 target price for the company. Morgan Stanley restated an “equal weight” rating and issued a $20.00 target price on shares of Horizon Pharma PLC in a research note on Tuesday, February 28th. Cowen and Company set a $20.00 target price on Horizon Pharma PLC and gave the company an “outperform” rating in a research note on Tuesday, May 9th. Finally, ValuEngine cut Horizon Pharma PLC from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Four equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $20.77.
Horizon Pharma PLC (NASDAQ:HZNP) traded up 0.88% during trading on Friday, hitting $10.29. The stock had a trading volume of 5,968,172 shares. Horizon Pharma PLC has a 52-week low of $9.45 and a 52-week high of $23.44. The firm’s 50-day moving average price is $11.36 and its 200-day moving average price is $14.96. The company’s market cap is $1.67 billion.
Horizon Pharma PLC (NASDAQ:HZNP) last posted its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by $0.04. The firm had revenue of $220.90 million for the quarter, compared to analysts’ expectations of $248.71 million. Horizon Pharma PLC had a positive return on equity of 21.51% and a negative net margin of 21.26%. The company’s revenue for the quarter was up 7.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.34 earnings per share. Analysts predict that Horizon Pharma PLC will post $0.84 EPS for the current fiscal year.
In other news, Director Michael G. Grey purchased 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 10th. The stock was purchased at an average cost of $9.48 per share, with a total value of $94,800.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 3.20% of the company’s stock.
Horizon Pharma PLC Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.